Absorption, pharmacokinetics and disposition properties of solid lipid nanoparticles (SLNs

Current Drug Metabolism

Volumn 13, Issue 4, 2012, Pages 447-456

  Wang, Jing ^a   Chen, Jing ^a   Ye, Niansong ^a   Luo, Zhiqiang ^a   Lai, Wenli ^a   Cai, Xiaoxiao ^a   Lin, Yunfeng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Absorption; Disposition; Distribution; Pharmacokinetics; Solid Lipid Nanoparticles (SLNs)

Indexed keywords

APOMORPHINE; CAMPTOTHECIN; CISPLATIN; CLOZAPINE; DEXAMETHASONE ACETATE; DIMINAZENE; DNA; DOXORUBICIN; DRUG CARRIER; INSULIN; LIPOSOME; MACROGOL; MACROGOL 2000; METHAZOLAMIDE; METHOTREXATE; NITRENDIPINE; OLIGONUCLEOTIDE; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYMER; POLYSORBATE 80; PRAZIQUANTEL; PROTEIN DERIVATIVE; SALVIANOLIC ACID B; SOLID LIPID NANOPARTICLE; STEARIC ACID; THYMOPENTIN; TOBRAMYCIN; TRANSFERRIN; UNINDEXED DRUG;

ARTICLE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG PENETRATION; EMULSION; HYDROPHILICITY; HYDROPHOBICITY; MACROMOLECULE; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; TISSUE DISTRIBUTION;

ABSORPTION; ANIMALS; DRUG CARRIERS; HUMANS; LIPIDS; NANOPARTICLES; TISSUE DISTRIBUTION;

EID: 84860604665     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012800166553     Document Type: Article

References (137)

1. Shoo, S.K.; Parveen, S.; Panda, J.J. The present and future of nanotechnology in human health care. Nanomedicine, 2007, 3(1), 20-31. (Pubitemid 46428187)
2. Park, J.H.; Lee, S.; Kim, J.H.; Park, K.; Kim, K.; Kwon, I.C. Polymeric nanomedicine for cancer therapy. Prog. Polym. Sci., 2008, 33(1), 113-137. (Pubitemid 350278530)
3. Sumer, B.; Gao, J. Therapeutic nanomedicine for cancer. Nanomedicine, 2008, 3(2), 137-140.
4. Kabanov, A.V.; Gendelman, H.E. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog. Polym. Sci., 2007, 32(8-9), 1054-1082. (Pubitemid 47198293)
5. Freitas, C.; Muller, R.H. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm., 1999, 47(2), 125-132. (Pubitemid 29185115)
6. Alonso, M.J. Nanomedicines for overcoming biological barriers. Biomed. Pharmacother., 2004, 58(3), 168-172. (Pubitemid 38479921)
7. Müller, R.H.; Mehnert, W.; Lucks, J.S.; Schwarz, C.; zur Mühlen, Z.; Weyhers, H.; Freitas, C.; Rühl,D. Solid lipid nanoparticles (SLN): an alternative colloidal carrier system for controlled drug delivery. Eur. J. Pharm. Biopharm., 1995, 41(1), 62-69.
8. Müller, R.H.; Lucks, J.S. Medication vehicles made of solid lipid particles (solid lipid nanospheres-SLN). Eur. Patent 0,605,497, 1996.
9. Müller, R.H.; Radtke, M.; Wissing, S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm., 2002, 242(1-2), 121-128.
10. Müller, R.H.; Keck, C.M. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J. Biotech., 2004, 113(1-3), 151-170. (Pubitemid 39237077)
11. zur Muhlen, A.; Schwarz, C.; Mehnert, W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm., 1998, 45(2), 149-155. (Pubitemid 28167741)
12. Müller, R.H.;. Mäder, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50(1), 161-177. (Pubitemid 30326695)
13. Morel, S.; Ugazio, E.; Cavalli, R.; Gasco, M.R. Thymopentin in solid lipid nanoparticles. Int. J. Pharm., 1996, 132(1-2), 259-261. (Pubitemid 26158724)
14. Morel, S.; Terreno, E.; Ugazio, E.; Aime, S.; Gasco, M.R. NMR relaxometric investigations of solid lipid nanoparticles (SLN) containing Gadolinium complexes. Eur. J. Pharm. Biopharm., 1998, 45(2), 157-163. (Pubitemid 28167742)
15. Schwarz, C.; Mehnert, W.; Lucks, J.; Müller, R.H. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J. Control Release, 1994, 30(1), 83-96. (Pubitemid 24173181)
16. Cortesi, R.; Esposito, E.; Luca, G.; Nastruzzi, C. Production of lipospheres as carriers for bioactive compounds. Biomaterials, 2002, 23(11), 2283-2294. (Pubitemid 34234829)
17. Lim, S.J., Kim, C.K. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int. J. Pharm., 2002, 243(1-2), 135-146.
18. Siekmann, B.; Bunjes, H.; Koch, M.M.H.; Westesen, K. Preparation and structural investigations of colloidal dispersions prepared from cubic monoglyceride-water phases. Int. J. Pharm., 2002, 244(1-2), 33-43. (Pubitemid 35245444)
19. Eldem, T.; Speiser, P.; Hincal, A. Optimization of spray-dried andcongealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharm. Res-Dordr., 1991, 8(1) 47-54.
20. Sjostrom, B.; Kaplun, A.; Talmon, Y.; Cabane, B. Structures of nanoparticles prepared from oil-in-water emulsions. Pharm. Res- Dordr., 1995, 12(1), 39-48.
21. Shahgaldian, P.; Da Silva, E.; Coleman, A.W.; Rather, B.; Zaworotko, M.J. Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters. Int. J. Pharm., 2003, 253(1-2), 23-38. (Pubitemid 36197828)
22. Dubes, A.; Parrot-Lopez, H.; Abdelwahed, W.; Degobert, G.; Fessi, H.; Shahgaldian, P.; Coleman, A.W. Scanning electron microscopy and atomic force microscopy imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins. Eur. J. Pharm. Biopharm., 2003, 55(3), 279-282. (Pubitemid 36561554)
23. Gasco, M.R. Method for producing solid lipid microspheres having a narrow size distribution. U.S. Patent 5,250,236, 1993.
24. Cavalli, R.; Marengo, E.; Rodriguez, L.; Gasco, M.R. Effects of some experimental factors on the production process of solid lipid nanoparticles. Eur. J. Pharm. Biopharm., 1996, 42(2), 110-115. (Pubitemid 26173946)
25. Cavalli, R.; Caputo, O.; Marengo, E.; Pattarino, F.; Gasco, M.R. The effect of the components of microemulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a series of model molecules. Pharmazie, 1998, 53(6), 392-396. (Pubitemid 28293594)
26. Igartua, M.; Saulnier, P.; Heurtault, B.; Pech, B.; Proust, J.E.; Pedraz, J.L.; Benoit, J.P. Development and characterization of solid lipid nanoparticles loaded with magnetite. Int. J. Pharm., 2002, 233(1-2), 149-157. (Pubitemid 34230427)
27. Wissing, S.A.; Kayser, O.; Müller, R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev., 2004, 56(9), 1257-1272. (Pubitemid 38510473)
28. Mathur, V.; Satrawala, Y.; Rajput, M.S.; Kumar, P.; Shrivastava, P.; Vishvkarma, A. Solid lipid nanoparticles in cancer therapy. Int. J. Drug Deliv., 2010, 2, 192-199.
29. Wissing, S.A.; Müller, R.H. The influence of solid lipid nanoparticles on skin hydration and viscoelasticity - in vivo study. Eur. J. Pharm. Biopharm., 2003, 56(1), 67-72. (Pubitemid 36802049)
30. MacGregor, K.J.; Embleton, J.K.; Lacy, J.E.; Perry, E.A.; Solomon, L.J.; Seager, H.; Pouton, C.W. Influence of lipolysis on drug absorption from the gastro-intestinal tract. Adv. Drug. Deliver. Rev., 1997, 25(1), 33-46. (Pubitemid 27107789)
31. Mallipeddi, R.; Rohan, L.C. Progress in antiretroviral drug delivery using nanotechnology. Int. J. Nanomedicine., 2010, 5, 533-547.
32. Mukherjee, S.; Ray, S.; Thakur, R.S. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian. J. Pharm. Sci., 2009, 71(4), 349-358.
33. Xiang, Q.Y.; Wang, M.T.; Chen, F.; Gong, T.; Jian, Y.L.; Zhang, Z.R.; Huang, Y. Lung-Targeting Delivery of Dexamethasone Acetate Loaded Solid Lipid Nanoparticles. Arch. Pharm. Res., 2007, 30(4), 519-525.
34. Bhalekar, M.R.; Pokharkar, V.; Madgulkar, A.; Patil, N.; Patil, N, Preparation and Evaluation of Miconazole Nitrate-Loaded Solid Lipid Nanoparticles for Topical Delivery. AAPS Pharm. Sci. Tech., 2009, 10(1), 290-296.
35. Manjunath, K.; Reddy, J.S.; Venkateswarlu, V. Solid Lipid Nanoparticles as Drug Delivery Systems. Methods. Find. Exp. Clin. Pharmacol., 2005, 27(2), 127-144.
36. Marengo, E.; Cavalli, R.; Caputo, O.; Rodriguez, L.; Gasco, M.R. Scale-up of the preparation process of solid lipid nanospheres. Int. J. Pharm., 2000, 205(1-2), 3-13.
37. Mehnert, W.; Mäder, K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev., 2001, 47(2-3), 165-196. (Pubitemid 32324113)
38. Dingler, A.; Gohla, S. Production of solid lipid nanoparticles (SLN): scaling up feasibilities. J. Microencapsul., 2002, 19(1), 11- 16. (Pubitemid 34083457)
39. Martins, S.; Sarmento, B.; Ferreira, D.C.; Souto, E.B. Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles. Int. J. Nanomedicine., 2007, 2(4), 595-607.
40. Zhang, X.G.; Miao, J.; Dai, Y.Q.; Du, Y.Z.; Yuan, H.; Hu, F.Q. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int. J. Pharm., 2008, 361(1-2), 239-244.
41. Suresh, G.; Manjunath, K.; Venkateswarlu, V.; Satyanarayana, V. Preparation, Characterization, and In Vitro and In Vivo Evaluation of Lovastatin Solid Lipid Nanoparticles. AAPS Pharm. Sci. Tech., 2007, 8(1), Article 24.
42. Puri, A.; Loomis1, K.; Smith, B.; Lee, J.H.; Yavlovich, A.; Heldman, E.; Blumenthal, R. Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic. Crit. Rev. Ther. Drug Carrier Syst., 2009, 26(6), 523-580.
43. Bhaskar, K.; Anbu, J.; Ravichandiran, V.; Venkateswarlu, V.; Rao, Y.M. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis., 2009, 8(6), 2-15.
44. Olbrich, C.; Gessner, A.; Kayser, O.; Müller, R.H. Lipid- drug conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J. Drug Target, 2002, 10 (5), 387-396.
45. Tabatt, K.; Sameti, M.; Olbrich, C.; Müller, R.H.; Lehr, C.M. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur. J. Pharm. Biopharm., 2004, 57(2), 155-162. (Pubitemid 38283690)
46. del Pozo-Rodríguez, A.; Delgado, D.; Solinís, M.A.; Gascón, A.R.; Pedraz, J.L. Solid lipid nanoparticles: Formulation factors affecting cell transfection capacity. Int. J. Pharm., 2007, 339(1-2), 261-268. (Pubitemid 46977611)
47. Olbrich, C.; Bakowsky, U.; Lehr, C.M.; Müller, R.H.; Kneuer, C. Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J. Control Release, 2001, 77(3), 345-355. (Pubitemid 33145485)
48. Heiati, H.; Tawashi, R.; Phillips, N.C. Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving, storage and lyophilization. J. Microencapsul., 1998,15(2), 173-184. (Pubitemid 28105133)
49. Rudolph, C.; Schillinger, U.; Ortiz, A.; Tabatt, K.; Plank, C.; Müller, R.H.; Rosenecher, J. Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm. Res., 2004, 21(9), 1662-1669. (Pubitemid 41184398)
50. Mukherjee, S.; Ray, S.; Thakur, R.S. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J. Pharm. Sci., 2009, 71(4), 349-358.
51. Xie, S.; Pan, B.; Wang1, M.; Zhu, L.; Wang, F.; Dong, Z.; Wang, X.; Zhou, W. Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles. Nanomedicine, 2010, 5(5), 693-701.
52. Fundaro, A.; Cavalli, R.; Bargoni, A.; Vighetto, D.; Zara, G.P.; Gasco, M.R. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: Pharmacokinetics and tissue distribution after i.v. administration to rats, Pharmacol. Res., 2000, 42(4), 337-343.
53. Müller, R.H.; Maassen, S.; Schwarz, C.; Mehnert, W. Solid lipid nanoparticles (SLN) as potential carrier for human use: Interaction with human granulocytes. J. Control. Release, 1997, 47(3), 261- 269. (Pubitemid 27220209)
54. Yu, B.T.; Sun, X.; Zhang, Z.R. Enhanced Liver Targeting by Synthesis of N1-Stearyl-5-Fu and Incorporation into Solid Lipid Nanoparticles. Arch. Pharm. Res., 2003, 26(12), 1096-1101.
55. Doijad, R.C.; Manvi, F.V.; Godhwani, D.M.; Joseph, R.; Deshmukh, N.V. Formulation and Targeting Efficiency of Cisplatin Engineered Solid Lipid Nanoparticles. Indian J. Pharm. Sci., 2008, 70(2), 203-207. (Pubitemid 351920197)
56. Yang, S.C.; Lu, L.F.; Cai, Y.; Zhu, J.B.; Liang, B.W.; Yang, C.Z. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control Release, 1999, 59(3), 299-307. (Pubitemid 29238174)
57. Moghimi, S.M. Mechanisms Regulating Body Distribution of Nanospheres Conditioned with Pluronic and Tetronic Block- Copolymers. Adv. Drug Deliver. Rev., 1995, 16(2-3), 183-193.
58. Luo, Y.; Chen, D.W.; Ren, L.X.; Zhao, X.L.; Qin, J. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J. Control. Release, 2006, 114(1), 53-59. (Pubitemid 44144503)
59. Tamayo-Esquivel, D.; Ganem-Quintanar, A.; Martinez, A.L.; Navarrete-Rodriguez, M.; Rodriguez-Romo, S.; Quintanar- Guerrero, D. Evaluation of the enhanced oral effect of omapatrilatmonolein nanoparticles prepared by the emulsification-diffusion method. J. Nanosci. Nanotechno., 2006, 6(9-10), 3134-3138. (Pubitemid 44579992)
60. Luo, Y.F.; Chen, D.W.; Ren, L.X.; Zhao, X.L.; Qin, J. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control. Release, 2006, 114 (1), 53-59. (Pubitemid 44144503)
61. Peng, Q.; Gong, T.; Zuo, J.; Liu, J.; Zhao, D.; Zhang, Z. Enhanced oral bioavailability of salvianolic acid B by phospholipid complex loaded nanoparticles. Pharmazie, 2008, 63(9),661-666.
62. Delie, F. Evaluation of nano- and microparticles uptake by the gastrointestinal tract. Adv. Drug Deliv. Rev., 1998, 34(2-3),221- 233. (Pubitemid 28535113)
63. Florence, A.T.; Hillery, M.; Jani, P.U. Factors affecting the oral uptake and traslocation of poly- stirene nanoparticles: Histological and analytical evidence. J. Drug Target., 1995, 3(1), 65-70.
64. Eyles, J.; Alpar, H.O.; Filed, D.A.; Lewis, D.A.; Keswick, M. The transfer of polystyrene microspheres from the gastrointestinal tract to the circulation after oral administration in the rats. J. Pharm. Pharmacol., 1995, 47(7), 561-565.
65. Peng, Q.; Zhang, Z.R.; Sun, X.; Zuo, J.; Zhao, D.; Gong, T. Mechanisms of phospholipid complex loaded nanoparticles enhancing the oral bioavailability. Mol. Pharm., 2010, 7(2), 565-575.
66. Li, R.; Jiang, S.M.; Liu, D.F.; Bi, X.Y.; Wang, F.Z.; Zhang, Q.; Xu, Q.W. A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide. J. Microencapsul., 2011, 28(2), 134-141.
67. Hu, L.D.; Tang, X.; Cui, F.D. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J. Pharm. Pharmacol., 2004, 56(12), 1527-1535. (Pubitemid 39601993)
68. Eldridge, J.H.; Hammond, C.J.; Meulbroek, J.A.; Staas, J.K.; Gilley, R.M.; Tice, T.R. Controlled vaccine release in the gutassociated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches. J. Control. Release, 1990, 11(1-3), 205-214.
69. Nishioka, Y.; Yoshino, H. Lymphatic targeting with nanoparticulate system. Adv. Drug Deliv. Rev., 2001, 47, 55-64. (Pubitemid 32209232)
70. Bocca, C.; Caputo, O.; Cavalli, R.; Gabriel, L.; Miglietta, A.; Gasco, M.R. Phagocytic uptake of fluorescent stealth and nonstealth solid lipid nanoparticles. Int. J. Pharm., 1998, 175(2), 185- 193. (Pubitemid 28517974)
71. Zhang, N.; Ping, Q.; Huang, G.; Xu, W.; Cheng, Y.; Han, X. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm., 2006, 327(1-2), 153-159. (Pubitemid 44667334)
72. Müller, R.H.; Ruhl, D.; Runge, S.; Schulze-Forster, K.; Mehnert, W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res., 1997, 14(4), 458-462. (Pubitemid 27205004)
73. Zara, G.P.; Cavalli, R.; Fundaro, A.; Bargoni, A.; Caputo, O.; Gasco, M.R. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol. Res., 1999, 40(3), 281-286. (Pubitemid 29435729)
74. Serrano, A.G.; Perez-Gil, J. Protein-lipid interactions and surface activity in the pulmonary surfactant system. Chem. Phys. Lipids, 2006, 141(1-2), 105-118. (Pubitemid 43728810)
75. B. Sarmento, S. Martins, D. Ferreira, E.B. Souto, Oral insulin delivery by means of solid lipid nanoparticles, Int. J. Nanomed., 2007, 2, 743-749.
76. Olbrich, C.; Gessner, A.; Schröder, W.; Kayser, O.; Müller R.H. Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene- cytotoxicity testing and mouse serum adsorption. J. Control. Release, 2004, 96(3), 425-435. (Pubitemid 38553921)
77. Ruckmani, K.; Sivakumar, M.; Ganeshkumar, P.A. Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. J. Nanosci. Nanotechno., 2006, 6(9-10), 2991-2995. (Pubitemid 44579973)
78. Paliwal, R.; Rai, S.; Vaidya, B.; Khatri, K.; Goyal, A.K.; Mishra, N.; Mehta, A.; Vyas, S.P. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine, 2009, 5(2), 184-191.
79. Zhang, N.; Ping, Q.; Huang, G.; Xu, W.; Cheng, Y.; Han, X. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm., 2006, 327(1-2), 153-159. (Pubitemid 44667334)
80. Hu, F.Q.; Yuan, H.; Zhang, H.H.; Fang, M. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int. J. Pharm., 2002, 239(1-2), 121-128. (Pubitemid 34615801)
81. Jung, T.; Kamm, W.; Breitenbach, A.; Kaiserling, E.; Xiao, J.X.; Kissel, T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm., 2000, 50(1), 147-160. (Pubitemid 30326694)
82. Cui, F.; Shi, K.; Zhang, L.; Tao, A.; Kawashina, Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: Preparation, in vitro characterization and in vivo evaluation. J. Control. Release, 2006, 114(2), 242-250. (Pubitemid 44291843)
83. Garcia-Fuentes, M.; Prego, C.; Torres, D.; Alonso, M.J. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur. J. Pharm. Sci., 2005, 25(1), 133-143. (Pubitemid 40602203)
84. Damge, C.; Vrancks, H.; Balschmidt, P.; Couvreur, P. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci., 1997, 86(12), 1407-1500.
85. Lin, Y.H.; Mi, F.L.; Chen, C.T.; Chang, W.C.; Peng, S.F.; Liang, H.F.; Sung, H.W. Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules, 2007, 8(1), 146-152.
86. Souto, E.B.; Müller,, R.H. Lipid Nanoparticles: Effect on Bioavailability and Pharmacokinetic Changes. Handb. Exp. Pharmacol., 2010, 197(2), 115-141.
87. McLennan, D.N.; Porter, C.J.H.; Charman, S.A. Subcutaneous drug delivery and the role of the lymphatics. Drug Discovery Today: Technologies, 2005, 2(1), 89-96. (Pubitemid 40946313)
88. Priano, L.; Esposti, D.; Esposti, R.; Castagna, G.; De Medici, L.; Fraschini, F.; Gasco, M.R.; Mauro, A. Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. J. Nanosci. Nanotechnol., 2007, 7(10), 3596-3601.
89. Holm, R.; Mullertz, A.; Christensen, E.; Hoy, C.E.; Kristensen, H.G. Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats. Eur. J. Pharm. Sci., 2001, 14(4), 331-337. (Pubitemid 33001626)
90. des Rieux, A.; Fievez, V.; Garinot, M.; Schneider, Y.J. ; Preat, V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release, 2006, 116(1), 1-27. (Pubitemid 44792295)
91. Hussain, N.; Jaitley, V.; Florence, A.T. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv. Drug Deliv. Rev., 2001, 50(1-2), 107-142. (Pubitemid 32727279)
92. Wasan, K.M. Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems. Drug Dev. Ind. Pharm., 2001, 27(4), 267-276. (Pubitemid 32531593)
93. Chakraborty, S.; Shukla, D.; Mishra, B.; Singh, S. Lipid-an emerging platform for oral delivery of drugs with poor bioavailability. Eur. J. Pharm. Biopharm., 2009, 73(1), 1-15
94. Cavalli, R.; Bargoni, A.; Podio, V.; Muntoni, E.; Zara, G.P.; Gasco, M.R. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J. Pharm. Sci., 2003, 92(5), 1085-1094. (Pubitemid 36523455)
95. Khoo, S.M.; Humberstone, A.J.; Porter, C.J.H.; Edwards, G.A.; Charman, W.N. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int. J. Pharm., 1998, 167(1-2), 155-164. (Pubitemid 28341517)
96. Hauss, D.J.; Fogal, S.E.; Ficorilli, J.V. Price, C.A.; Roy, T.; Jayaraj, A.A.; Keirns, J.J. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water soluble LTB4 inhibitor. J. Pharm. Sci., 1998, 87(2), 164-169. (Pubitemid 28081323)
97. Delie, F. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv. Drug Deliv. Rev., 1998, 34(2-3), 221-233 (Pubitemid 28535113)
98. Bargoni, A.; Cavalli, R.; Caputo, O.; Fundaro, A.; Gasco, M.R.; Zara, G.P. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm. Res., 1998, 15(5), 745-750. (Pubitemid 28275652)
99. Pappo, J.; Ermak, T.M.; Steger, H.J. Monoclonal antibody directed targeting of fluorescent polystyrene microspheres to Peyer's patch M cells. Immunol, 1991, 73(3), 277-280.
100. Jepson, M.A.; Simmons, N.L.; O'Hagan, D.T.; Hirst, B.H. Comparison of poly(DL-lactide-co-glycolide) and polystyrene microsphere targeting to intestinal M cells. J. Drug Target., 2003, 11(5), 269-272.
101. des Rieux, A.; Fievez, V.; Garinot, M.; Schneider, Y.J. ; Preat, V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release, 2006, 116(1), 1-27. (Pubitemid 44792295)
102. Zara, G.P., Cavalli, R.; Bargoni, A.; Fundaro, A.; Vighetto, D.; Gasco, M.R. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: Pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target., 2002, 10(4), 327-335. (Pubitemid 34746314)
103. Gasco, M.R.; Priano, L.; Zara, G.P. Solid lipid nanoparticles and microemulsions for drug delivery: the CNS. Prog. Brain Res., 2009, 180, 181-192.
104. Patel, S.; Chavhan, S.; Soni, H.; Babbar, A.;. Mathur, R.; Mishra, A.; Sawant, K. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J. Drug Target., 2010, 1-7.
105. Kaur, I.P.; Bhandari, R.; Bhandari, S.; Kakkar, V. Potential of solid lipid nanoparticles in brain targeting. J. Control. Release, 2008, 127(2), 97-109.
106. Joshi, M.D.; Müller, R.H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm., 2009, 71(2), 161- 172.
107. Saha, A.; Ramakrishnan, S. Unimolecular micelles and reverse micelles based on hyperbranched polyethers-Comparative study of AB2+ A-R and A2+B3+A-R type strategies. J. Polymer Sci. Part A: Polymer Chem., 2009, 47(1), 80-91.
108. Hoet, P.H.M.; Brüske-Hohlfeld, I.; Salata, O.V. Nanoparticles - known and unknown health risks. J. Nanobiotechnol., 2004, 2, 12.
109. Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliver. Rev., 2001, 47(1), 65-81. (Pubitemid 32209233)
110. Storm, G.; Belliot, S.O.; Daemen, T.; Lasic, D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Deliver. Rev., 1995, 17(1), 31-48.
111. Manjunath, K.; Venkateswarlu, V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Control. Release, 2005, 107(2), 215-228. (Pubitemid 41319672)
112. Manjunath, K.; Venkateswarlu, V. Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Drug Target., 2006, 14(9), 632-645. (Pubitemid 44712359)
113. Zara, G.P., Cavalli, R.; Bargoni, A.; Fundaro, A.; Vighetto, D.; Gasco, M.R. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target., 2002, 10(4), 327-335. (Pubitemid 34746314)
114. Gupta, Y.; Jain, A.; Jain, S.K. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J. Pharm. Pharmacol., 2007, 59(7), 935-940. (Pubitemid 47051073)
115. Yang, S.; Zhu, J.; Lu, Y.; Liang, B.; Yang, C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res-Dordr., 1999, 16(5), 751-757. (Pubitemid 29227107)
116. Senthilkumar, K.S.; Saravanan, K.S.; Chandra, G.; Sindhu, K.M.; Jayakrishnan, A. Mohanakumar, K.P. Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemiparkinsonism. Behav. Brain Res., 2007, 184(1), 11-18. (Pubitemid 47411588)
117. Calvo, P.; Gouritin, B.; Chacun, H.; Desmaele, D.; D'Angelo, J.; Noel, J.P.; Georgin, D.; Fattal, E.; Andreux, J.P.; Couvreur, P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res-Dordr., 2001, 18(8), 1157-1166. (Pubitemid 32900402)
118. Zara, G.P.; Bargoni, A.; Cavalli, R.; Fundaro, A.; Vighetto, D.; Gasco, M.R. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J. Pharm. Sci., 2002, 91(5) 1324-1333. (Pubitemid 34651194)
119. Baert, L.; van't Klooster, G.; Dries, W.; Francois, M.; Wouters, A.; Basstanie, E.; Iterbeke, K.; Stappers, F.; Stevens, P.; Schueller, L.; Van Remoortere, P.; Kraus, G.; Wigerinck, P.; Rosier, J. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur. J. Pharm. Biopharm., 2009, 72(3), 502-508.
120. Xie, S.; Zhu, L.; Dong, Z.; Wang, X.; Wang, Y.; Li, X.; Zhou, W. Preparation, characterization and pharmacokinetics of enrofloxacinloaded solid lipid nanoparticles: Influences of fatty acids. Colloids Surf. B. Biointerfaces, 2011, 83, 382-387.
121. Almelda, A.J.; Souto, E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug. Deliver. Rev., 2007, 59(6), 478-490. (Pubitemid 47260710)
122. Liu, J.; Gong, T.; Wang, C.G.; Zhong, Z.R.; Zhang, A.R. Solid lipid nanoparticles loaded with insulin by sodium cholatephosphatidylcholine- based mixed micelles: Preparation and characterization. Int. J. Pharm., 2007, 340(1-2), 153-162. (Pubitemid 47044961)
123. Liu, H.; Gong, T.; Fu, H.L.; Wang, C.G.; Wang, X.L.; Chen, Q.; Zhang, Q.; He, Q.; Zhang, Z.R. Solid lipid nanoparticles for pulmonary delivery of insulin. Int. J. Pharm., 2008, 356(1-2), 333- 344.
124. Kumar, M.; Misra, A.; Babbar, A.K.; Mishra, A.K.; Mishra, P.; Pathak, K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. Pharm., 2008, 358(1-2), 285- 291.
125. Cavalli, R., Gasco, M.R.; Chetoni, P.; Burgalassi, S.; Saettone, M.F. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm., 2002, 238(1-2), 241-245. (Pubitemid 34457892)
126. Sznitowska, M.; Gajewska, M.; Janicki, S.; Radwanska, A.; Lukowski, G. Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. Eur. J. Pharm. Biopharm., 2001, 52(2), 159-163. (Pubitemid 32755894)
127. Seyfoddin, A.; Shaw, J.; Al-Kassas, R. Solid lipid nanoparticles for ocular drug delivery. Drug Deliver., 2010, 17(7), 467-489.
128. Suresh, R.J.; Venkateswarlu, V. Novel delivery systems for drug targeting to the brain. Drug Future, 2004, 29(1), 63-83. (Pubitemid 38252080)
129. Holm, R.; Müllertz, A.; Christensen, E.; Hoy C.E.; Kristensen, H.G. Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats. Eur. J. Pharm. Sci., 2001, 14(4), 331-337. (Pubitemid 33001626)
130. Lu, W.; He, L.C.; Wang, C.H.; Li,Y.H.; Zhang, S.Q. The use of solid lipid nanoparticles to target a lipophilic molecule to the liver after intravenous administration to mice. Int. J. Biol. Macromol., 2008, 43(3), 320-324.
131. Martins, S.; Sarmento, B.; Ferreira, D.C.; Souto, E.B. Lipid-based colloidal carriers for peptide and protein delivery Cliposomes versus lipid nanoparticles. Int. J. Nanomed., 2007, 2, 595.
132. Olbrich, C.; Müller, R.H. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int. J. Pharm., 1999, 180(1), 31- 39. (Pubitemid 29131440)
133. Gupta, Y.; Jain, A.; Jain, S.K. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J. Pharm. Pharmacol., 2007, 59(7), 935-940. (Pubitemid 47051073)
134. Litzinger, D.C.; Buiting, A.M.J.; van Rooijen, N.; Huang, L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly (ethylene glycol)-containing liposomes. Biochim. Biophys. Acta., 1994, 1190(1), 99-107. (Pubitemid 24066264)
135. Chen, D.B.; Yang, T.; Lu, W.L.; Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem. Pharm. Bull., 2001, 49, 1444-1447. (Pubitemid 33043274)
136. Suresh, G.; Manjunath, K.; Venkateswarlu, V.; Satyanarayana, V. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. Aaps. Pharmscitech, 2007, 8(1), 162-170.
137. Almeida, A.J.; Souto, E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliver. Rev., 2007, 59(6), 478-490. (Pubitemid 47260710)